Work

Experience with tafamidis in a patient with transthyretin amyloidosis

Year: 2020

Type: article

Abstract: Transthyretin amyloidosis (ATTR) is a threatening and severe genetic disease characterized by damages to organs and systems caused by a pathological protein transthyretin produced in the liver. Clinical manifestations of this disease vary from injuries of the nervous system to injuries of the cardiovascular system. Prognosis for ATTR-amyloidosis remains unfavorable. The absence of pathognomonic symptoms complicates diagnostics of this disease, which tends to simulate other conditions. At present, medicines exist, which are pathogenetic in the treatment of ATTR-amyloidosis. The article describes a clinical case of ATTR-amyloidosis with primary heart injury complicated with functional class III chronic heart failure during the tafamidis treatment.

Source: Kardiologiia

DOI: 10.18087/cardio.2020.3.n824

Authors: S. N. Nasonova, I. V. Zhirov, M. M. Magomedov, M. A. Saidova, Yu. F. Osmolovskaya, S. N. Tereschenko

Institutions: Ministry of Health of the Russian Federation, National Medical Research Center of Cardiology, Russian Medical Academy of Continuous Professional Education

Language: Russian

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Internal Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W3021159541

FWCI: 0.333

Cites: 5

Cited by: 5

Related to: 10